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Amongst 17 patients with hepatic focal nodular hyperplasia (FNH) encountered at Westmead Hospital
between 1981 and 1990, FNH was found in association with hepatocellular carcinoma (HCC) in three (3/
17), one male and two females, one of whom also had peliosis and an hepatic adenoma. FNH was also
found in association with other conditions which may affect hepatic function, structure or circulation,
including chronic obstructive airways disease (2), congestive cardiomyopathy (1), chronic active
hepatitis (1), granulomatous hepatitis (1), coeliac artery stenosis (1) and metastatic malignant mela-
noma (1).
This report, derived from our experience with FNH over 10 years draws attention to a possible link
between FNH, hepatic malignancy and conditions which may disturb the hepatic circulation. We suggest
that patients with FNH should be investigated thoroughly and an aggressive management policy should
be adopted.
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INTRODUCTION
Hepatic focal nodular hyperplasia (FNH) is currently believed to be a benign,
usually asymptomatic liver lesion 1. Its aetiology remains uncertain despite con-
siderable speculation. Factors believed to play an aetiological role include pre-
existing vascular anomaly, vascular injury (e.g. thrombosis) and long term oral
contraceptive medication (OCM) ingestion2’3’4.
It has been believed that FNH does not undergo malignant change lbut recently
documented associations with liver cancer warrant consideration3’4’5. We report a
further three cases of hepatocellular carcinoma (HCC) associated with FNH, two
of them in long term OCM users.
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PATIENTS AND METHODS
The records of all 17 patients admitted to Westmead Hospital with a proven
diagnosis of hepatic FNH from January 1981 to January 1990 were reviewed. The
following information was extracted from the case records: age, sex, duration of
OCM usage, mode of presentation, relevant laboratory results, method of biopsy,
method of treatment (conservative or surgical), tumour histology, location and size
and long term follow up.
RESULTS
Age and Sex Incidence
There were 15 females and 2 males with FNH. Median age was 36 years (range
27-67)
Clinical Features
In 6 patients FNH was an incidental finding at operation for some other non-
hepatic problem. There were 3 other patients with asymptomatic FNH, 2 picked up
during investigation for abnormal liver function tests and one because of an upper
abdominal mass found on routine examination. Six patients had symptomatic FNH,
causing abdominal pain (4), abdominal discomfort (2), fatigue (1), anorexia (1) or
loss of weight (1). Symptoms in the remaining two were due to HCC. There were
positive findings on physical examination in 4 patients with FNH (not associated
with other pathology); a non-tender upper abdominal mass in 3 and spider naevi
and hepatomegaly in one.
Oral Contraceptive Medication (OCM)
Nine of the 15 females had used OCM at some time. Detailed information about
OCM usage was available in 7, with a mean duration of OCM usage in these of 10
years (range 4 18 years). Two of the 15 females had FNH associated with HCC,
one of which was the fibrolamellar variant. Both had been on OCM.
Laboratory Results
None of the patients was anaemic. Liver function tests were available in 16 and in
11 of these there was evidence of impairment of hepatic function. Liver function
tests were severely disturbed (raised serum alkaline phosphatase, bilirubin and
transaminases) in two patients, both with unresectable hepatic malignancy as well
as FNH. In the remaining 9 patients the most common liver function test
abnormality was a raised serum alkaline phosphatase. This was elevated to twice
the normal level in three patients, one of whom had FNH, HCC, adenoma and
peliosis. Another had FNH and chronic active hepatitis and a third had FNH alone.
Serum bilirubin was also slightly elevated in the case with FNH and chronic active
hepatitis but was normal in all others. In the remaining 6 patients with disturbances
of liver function, bilirubin was normal and changes in SAP and transaminases wereFOCAL NODULAR HYPERPLASIA 173
minor. Serological tests for hepatitis B, alpha-feto-protein and carcino-embryonic
antigen were done in 13 patients and were consistently negative.
Organ Imaging
Imaging procedures were’ not performed in the 6 cases where an unexpected
hepatic mass found at laparotomy proved to be FNH. Ultrasound and CAT
scanning and angiography were used in the remaining 11. In all, scanning and
angiography revealed solid, vascular hepatic lesions, findings consistent with, but
not specifically diagnostic of, FNH. Central scars were reported in 4 but found on
histopathology in only two of these. On angiography large feeding vessels were
noted in 2, spokewheel vascularity in 1. In 2 cases central scarring was found at
histopathology which had not been seen on organ imaging. In the 3 cases where
FNH and HCC coexisted organ imaging could not differentiate between the two.
On IV contrast CAT scanning all 3 show rapid opacification equivalent to that of
the adjacent liver parenchyma. Similarly, in one case where FNH and malignant
melanoma coexisted, imaging revealed solid, vascular lesions which were not
specifically diagnostic and could not be differentiated from each other on the basis
of radiological findings.
Histopathology
This was the method of final diagnosis in all but 2 of the 17 cases. A diagnosis of
FNH was made on cytology in 2 cases (2/17) early in this series. One of these
patients had refused laparotomy, both have had stable lesions on follow-up organ
imaging studies. Their FNH studies yielded somewhat dysplastic cells consistent
with but not specific for FNH. The remainder underwent laparotomy and open
biopsy (15/17) allowing definitive histological diagnosis in 15 of the 17. FNH was
associated with HCC in 3 patients; fibrolamellar HCC in one of these, primary
HCC in a second and peliosis, liver cell adenoma and primary HCC in the third
(Table 1). FNH was seen in the right lobe of the liver in 11 cases, the left lobe in 4
and both lobes in 2. Tumour size was measured by the pathologist in those that
were resected and by the radiologist on CT or ultrasound scans in those treated
conservatively. Mean tumour size was 7 cm maximum diameter in 12 patients,
there being no record of tumour size in five.
Table Diseases found in association with FNH
lntrahepatic Extrahepatic
HCC 2
HCC + Adenoma + Peliosisl
Melanoma
Chr. active hepatitis
Granulomatous hepatitis
COAD 3
Cardiomyopathy
Cholelithiasis
Coeliac Artery Stenosisl
Diabetes
Gastric Ca.174 N. TAIT ET AL.
Associated Illnesses
A number of other intrahepatic and extrahepatic conditions which could affect
hepatic homeostasis were seen in conjunction with FNH. These are listed in Table
1.
Treatment and Follow-up
Of the 9 patients offered surgical treatment one refused. Eight were offered
conservative treatment and are on long term follow up. Tumour size in this group
ranged from 1 to 10 cm. Seven of the 8 had single lesions and one had 2 lesions.
None of these have shown any change in the size or imaging characteristics of their
lesions during follow-up ranging from 1 to 10 years.
One female had inoperable metastatic melanoma diagnosed at laparotomy and
her FNH was not resected. One male with inoperable HCC and FNH underwent
percutaneous transarterial chemoembolisation using adriamycin and lipiodol. He is
on regular follow up with no evidence of progression of either his FNH or HCC 3
months after treatment. One was lost to follow up. Sixteen patients are known to
be alive with a median follow up of 3.5 years (range 2 months 10 years).
DISCUSSION
The currently accepted view of FNH is of a static, benign liver lesion arising from
reparative rather than neoplastic processes1’6. This may not be correct. An increas-
ing number of reports associating FNH with primary HCC and its fibrolamellar
variant3’4’5’7 lead to a growing feeling supported by the material in this paper-
that FNH should not be so lightly dismissed. In our series of 17 patients with FNH,
six had coexistent hepatic lesions. Three had HCC and one of these also had
peliosis and an hepatic adenoma. Two had hepatic inflammatory changes, chronic
active hepatitis in one and granulomatous hepatitis in the other. One had hepatic
metastases from malignant melanoma.
Five of our patients had extrahepatic illnesses which could disturb hepatic
circulation. One had a severe cardiomyopathy with resistent congestive cardiac
failure. Another had median arcuate ligament compression with marked stenosis of
the coeliac artery. Three had chronic obstructive airways disease, two due to
smoking and one due to chronic bronchitis and smoking though none had deve-
loped cor pulmonale.
There is a single report of an association between multiple FNH and vascular
malformations elsewhere in the body. In addition, patients with multiple FNH in
that series developed a higher than expected number of central nervous system
tumours8. We have not observed this, but we stress that we have not sought it,
being unaware of this reported association until recently.
It is difficult to know what the prevalence ofFNH is in the community. We know,
from pursuing the diagnosis in 64 patients with the chance finding of a mass in the
liver on organ imaging that 7 of the 64 had areas of FNH. We have previously
reported on 36 of these hepatic incidentalomas9. FNH may thus present a diagnos-
tic problem when an unexpected hepatic tumour is found during investigation of
other abdominal problems. We stress that there are no clinical, biochemical,FOCAL NODULAR HYPERPLASIA 175
serological or organ imaging characteristics nor specific tumour markers which will
definitively distinguish FNH from adenoma or HCC1. Fine needle aspiration
cytology may be helpful, but will commonly produce dysplastic cells compatible
with origin in a well differentiated HCC. It is, therefore, imperative that clinicians
seek a definitive diagnosis. For these reasons, open biopsy may be necessary.
It is usually taught that FNH should be removed if symptomatic, but otherwise is
of no significance6. Until now, our management policy has largely followed these
traditional guidelines based on a view of FNH as a non-neoplastic, rather inert
lesion. However, increasing concern about the association ofFNH with malignancy
now leads us to suggest that the traditional management regime should be
modified. We would now suggest that the diagnosis should be pursued until it is
confirmed, and a laparotomy and open biopsy should be carried out. When the
diagnosis has been made, a thorough search should be made for malignancy both in
the liver and elsewhere in the abdomen. A finding of multiple FNH should initiate
screening for vascular malformations elsewhere, and probably cerebral CT scan-
ning to exclude central nervous system tumours8. Areas ofFNH should be removed
wherever possible. Removal should be with a narrow margin of normal tissue, just
as if the lesion was a benign neoplasm. If a conservative treatment option is chosen
or the lesions are incompletely excised, we now recommend that such patients be
regularly screened by organ imaging looking for growth ofFNH lesions. Follow-up
and screening should be done by a specialist HPB Unit on at least a yearly basis.
The long term history of FNH is not yet known. Our understanding of it is still
evolving. It is not clear whether FNH is a marker of some other premalignant
change in the liver, or whether it is in itself premalignant. There are suggestions
that FNH may progress to fibrolamellar carcinoma, and it is of interest that one of
our patients had two areas ofFNH adjacent to a fibrolamellar carcinoma. Suspicion
that hepatic FNH may be associated with or serve as a marker of more sinister
disease is heightened by reports of FNH and HCC coexisting. It is important that
clinicians following any number of patients with FNH by regular observation
should report their results over many years.
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INVITED COMMENTARY
Focal nodular hyperplasia is a relatively rare, apparently benign lesion which
occurs in the liver of patients without cirrhosis. It presents as a hepatic mass lesion,
single or multiple liver lesion and is becoming increasingly diagnosed. It’s occur-
rence has been related to the use of oral contraceptive but the relationship is less
strong than that of hepatic adenoma. Moreover it is found in patients with no
history of oral contraceptive use as well as in men. The present series is a ten year
review of 17 patients with focal nodular hyperplasia of the liver presenting to a
single unit. In the past there has been confusion concerning the nomenclature and
histological diagnosis of this condition. Although the features are now well
established- a central scarred area surrounded by fibrous bands containing
proliferating bile ducts, normal hepatocytes and a degree of chronic lymphocytic
infiltration, it might have been useful if the authors had included a brief histological
description to define their criteria for the diagnosis.
The existing literature on this condition is littered with case reports, with one or
two notable exceptions and so a carefully investigated and followed up series is
most welcome. One other series with a 16 year follow up has been reported recently
from London but the Australian authors have introduced differing perspectives by
first raising the spectre of malignancy associated with focal nodular hyperplasia and
second introducing the concept that extrahepatic disease may contribute to its
aetiology.
Focal nodular hyperplasia is commonly asymptomatic. More than 50% of the
patients studied had the mass lesion discovered incidentally and this is in keeping
with other reports. The first problem is reaching a definitive diagnosis. The surgeon
may often be called upon to confirm the diagnosis by open biopsy according to the
present authors. They were unable preoperatively to confidently discriminate focal
nodular hyperplasia from hepatocellular carcinoma in the three cases where the
two coexisted, or focal nodular hyperplasia from melanoma metastases using a
combination of computerised tomography, ultrasonography and angiography. This
was also the experience of Mayo clinic reported 19832. Laparotomy and open
biopsy was thus required for diagnosis in 15 of the 17 cases reported. This finding
contrasts with more recent studies suggesting that a confident diagnosis can be
reached preoperatively in about 80% of cases and in one report without the needFOCAL NODULAR HYPERPLASIA 177
for histological confirmationS! To rationalise this argument there seems little doubt
that the best method of confirming the diagnosis is open biopsy. If the lesion is
symptomatic and will need to be removed anyway, then biopsy is unnecessary. If
however conservative management or embolisation therapy is being considered
then a percutaneous biopsy examined by a pathologist experienced in liver disease
should be required.
Inseparable from the diagnostic manoeuvres is the consideration of what should
the treatment be? As the authors correctly aver the current view, based on a limited
experience of a rare problem, is that focal nodular hyperplasia is rarely symptoma-
tic, will rarely give rise to complications such as bleeding and has a low if any
potential for malignant transformation. Resection of the lesion or lesions undoub-
tedly solves the problem and this is attractive given that the majority are in the right
lobe and surgery in young patients with normal liver function is attended by a low
operative morbidity and mortality. Embolisation has been proposed to avoid the
necessity for surgery and on the small numbers reported it seems to be effective1’3.
The bulk of reported cases have however been managed conservatively and the
accumulated data suggest that focal nodular hyperplasia remains static after
diagnosis. There are no reported cases of hepatocellular carcinoma occurring in
patients undergoing close follow up for this condition. Yet the association of focal
nodular hyperplasia with hepatocellular carcinoma is inescapable. It is however
something of a "chicken and egg" scenario. The apparent evolution of focal
nodular hyperplasia into the fibrolamellar variant of hepatocellular carcinoma has
been reported4. Indeed the similarities between the two lesions are striking. Almost
indistinguishable grossly, they may share a common central scar and fibrous bands5.
Myelofibroblast like cells can be demonstrated in each on electron microscopy
6 and
flow cytometric analyses are very similar5. On the other hand hepatocellular
carcinoma has not been shown to develop after a diagnosis of focal nodular
hyperplasia has been made and there is some evidence to suggest that the latter
may occur as a response to alterations in hepatic haemodynamics. For example the
kind of alteration which might result from a developing hepatocellular carcinoma.
The evidence for altered intrahepatic blood flow causing focal nodular hyperplasia
is based around its association with other liver lesions particularly haemangiomas7.
In autopsy studies the frequency of occult haemangiomas and focal nodular
hyperplasia is approximately the same being around 0.3%. It is thought that the
hyperplastic nodules develop in response to transient ischaemia. It has also been
suggested that the central fibrous scar represents the end stage of a progressive
sclerosis/thrombosis of a vascular malformation. The disturbance of haemodyna-
mics associated with intrahepatic lesions is a relatively straightforward concept to
grasp. The authors second main point concerning the association of focal nodular
hyperplasia with extrahepatic disease is a little more tenuous. Nodular hyperplasia
has been associated with a number of systemic disorders which can affect blood
vessels, such as rheumatoid arthritis and myeloproliferative disorders. Interestingly
there are also associations with immune disorders but no specific reference to
acquired immune deficiency. The present series includes one patient with a
cardiomyopathy and one with coeliac artery stenosis in whom it is entirely possible
that hepatic haemodynamics could be abnormal. In the two patients described with
chronic obstructive airways disease, without cor pulmonale, it is less convincing and
with such small numbers their speculation on an extrahepatic aetiology remains just
that.178 N. TAIT ETAL.
In their final recommendations the authors suggest that patients with focal
nodular hyperplasia should be investigated thoroughly. This is common sense.
Whether or not focal nodular hyperplasia evolves into hepatocellular carcinoma the
two are associated and it behoves the clinician to exclude carcinoma before settling
for a conservative option.
Focal nodular hyperplasia is becoming more commonly diagnosed and cannot be
ignored. Preoperative diagnosis can never be 100% confident. Open biopsy is the
best method of confirming the diagnosis and excision biopsy should correct the
problem once and for all. The frequency with which focal nodular hyperplasia and
hepatocellular carcinoma seem to occur together in resection specimens allows no
room for complacency. Embolisation therapy may have something to offer where
the diagnosis is unequivocal and there is contraindication to surgery. Otherwise,
surgical resection would be the treatment of choice. This will avoid the small but
real risk of missing an associated, curable heptaocellular carcinoma.
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INVITED COMMENTARY
The malignant potential of the so-called "benign" liver tumors (liver cell adenoma
and focal nodular hyperplasia [FNH]) remains in question in spite of 25 years of
increasing interest and experience with these rare lesions. The co-incidence of focal
nodular hyperplasia with carcinoma in 3 of 17 patients with focal nodular hyperpla-
sia reported by Muguti et al. is frightening indeed. Although many surgeons are
concerned about the pre-malignant nature of liver cell adenoma, few have recom-
mended resection for FNH to "prevent cancer" once a histologic diagnosis was
firmly established. Should this recommendation change?
In spite of considerable interest and an ongoing cooperative effort with others
around the world who share that interest, this writer cannot take a strong stand on
either side of this question in 1991. My confusion is based upon:
1. Although agreement about histologic differences between liver cell adenoma
and FNH are much clearer than they were two decades ago, some tumors have
specific features of both lesions, and different pathologists may make different
calls.
2. Although nodular lesions with the histologic criteria for malignancy are easy
to produce in the livers of experimental animals and have been found in humans
undergoing androgen therapy, such lesions may not always have the biologic
potential to spread and to kill if untreated.
3. Similarly, the clinical significance of a focus of histologic cancer found within
the substance of a resected liver cell adenoma remains unknown. The parallel with
thyroid and breast carcinoma is obvious. However, the risk of "prophylactic" organ
removal for the liver far outweights that for breast or thyroid.
4. No convincing report of definite malignant change in a solitary benign liver
tumor left in place is yet known to this writer. However, at least two patients with
proven multiple liver cell adenomas have eventually developed primary liver cancer
while under observation, one dying of her disease and the other requiring
transplantation.
Perhaps when each and all of the leads suggested by others are brought together,
there will be enough evidence to settle this question, but it may turn out to be much
like the problem of the colon polyp and cancer.
More specific details about the geography of the benign and malignant compo-
nents of the tumors in this Australian report would be useful in trying to understand
any relationships. Was the cancer within the "benign" tumor or were two discrete
lesions separated widely by normal liver tissue?
I had only a few other minor problems with this paper. I do not believe that
diagnosis of FNH can be made by aspiration cytology. I know of no evidence that
suggests that a margin of normal liver tissue need be taken when resecting a benign
liver tumor, although only the hemangioma has a true capsule which allows easy
enucleation. And lastly, can one make a diagnosis of focal nodular hyperplasia in a
liver diffusely involved with chronic active inflammation and repair? I think not,
since nodular hyperplasia is part and parcel of any such process and may be either
focal or diffuse.180 N. TAIT ETAL.
We should be grateful for the report of this Australian experience. It has raised
the importance of resolving this issue. It would be foolish to accept the probability
of an association between FNH and primary liver cancer on the basis of this
anecdotal evidence. It would be even more foolish to deny the possibility of such an
association. Would I recommend liver transplantation for a patient proven to have
multiple FNH tumors geographically not amenable to local resection? No, I would
not. Not yet.
James H. Foster
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